title: Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
abstract: An underlying cause of type III hyperlipoproteinemia is the presence of variant forms of apolipoprotein (apo) E that are defective in binding to apo B,E low density lipoprotein receptors. This disorder is associated almost exclusively with the apo E2/2 phenotype. However, structural and functional heterogeneity have been demonstrated within this phenotype. The apo E2(Arg158----Cys) variant, displaying 1% of normal apo E3 binding activity, is the most defective known form. In this study, we describe a method in which a pair of 19-mer synthetic oligonucleotide probes were used to distinguish between DNA coding for arginine or cysteine at position 158 in apo E. The specificity of the probes was demonstrated by using DNA from subjects whose apo E protein sequence or phenotype was known. The probes were used to screen a French-Canadian population of 34 apo E2/2 subjects to determine the frequency of the apo E2(Arg158----Cys) variant. All 34 subjects, most of whom displayed clinical or biochemical features of type III hyperlipoproteinemia, were found to be homozygous for apo E2(Arg158----Cys), strongly suggesting that this variant is the most common form of apo E2 within this ethnic and clinical population. In addition, the utility of this approach in detecting new apo E mutants was demonstrated when DNA from one of the apo E3/3 control subjects, whose family has a history of hyperlipidemia and coronary artery disease, reacted with both probes. This result suggests that this subject is heterozygous for normal apo E3 and a new apo E3 variant that is likely to be functionally equivalent to apo E2(Arg158----Cys).
authors.affiliation: Gladstone Foundation Laboratories, University of California, San Francisco, CA 94140.
authors.forename: K H
authors.initials: KH
authors.lastname: Weisgraber
authors.forename: Y M
authors.initials: YM
authors.lastname: Newhouse
authors.forename: J M
authors.initials: JM
authors.lastname: Taylor
authors.forename: B
authors.initials: B
authors.lastname: Tuan
authors.forename: A C
authors.initials: AC
authors.lastname: Nestruck
authors.forename: J
authors.initials: J
authors.lastname: Davignon
authors.forename: R W
authors.initials: RW
authors.lastname: Mahley
mesh_terms: D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics*; D001120:Arginine / Q000235:genetics*; D001483:Base Sequence; D003545:Cysteine / Q000235:genetics*; D004247:DNA / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D014644:Genetic Variation; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009693:Nucleic Acid Hybridization; D015345:Oligonucleotide Probes; D011792:Quebec
chemical_list: D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D015345:Oligonucleotide Probes; D004247:DNA; D001120:Arginine; D003545:Cysteine